Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $38,171.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CEO Cedric Francois sold 1,900 shares of the company's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $20.09, for a total value of $38,171.00. Following the completion of the transaction, the chief executive officer owned 342,333 shares of the company's stock, valued at $6,877,469.97. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Thursday, July 17th, Cedric Francois sold 19,725 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $20.21, for a total value of $398,642.25.
• On Monday, July 14th, Cedric Francois sold 137,465 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $20.19, for a total value of $2,775,418.35.

Apellis Pharmaceuticals Price Performance

APLS traded down $0.57 on Friday, reaching $19.47. The stock had a trading volume of 1,842,831 shares, compared to its average volume of 2,369,900. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $41.94. The firm has a 50-day moving average of $18.23 and a 200-day moving average of $22.64. The company has a current ratio of 4.08, a quick ratio of 3.62 and a debt-to-equity ratio of 2.76. The company has a market capitalization of $2.45 billion, a price-to-earnings ratio of -10.88 and a beta of 0.67.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The business had revenue of $149.90 million for the quarter, compared to the consensus estimate of $197.61 million. During the same quarter in the previous year, the company earned ($0.54) EPS. The firm's revenue for the quarter was down 3.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

APLS has been the topic of a number of research analyst reports. Needham & Company LLC dropped their price target on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $44.00 price target on the stock. Royal Bank Of Canada dropped their price target on Apellis Pharmaceuticals from $21.00 to $18.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Scotiabank dropped their price target on Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Thursday, May 8th. Finally, Wells Fargo & Company lifted their target price on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research report on Monday, June 2nd. Nine equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after acquiring an additional 758 shares during the period. Assetmark Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 3,938.7% in the first quarter. Assetmark Inc. now owns 1,252 shares of the company's stock worth $27,000 after acquiring an additional 1,221 shares during the period. Parallel Advisors LLC boosted its holdings in shares of Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock worth $33,000 after acquiring an additional 855 shares during the period. Signaturefd LLC boosted its holdings in shares of Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after acquiring an additional 918 shares during the period. Finally, GF Fund Management CO. LTD. boosted its holdings in shares of Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company's stock worth $70,000 after acquiring an additional 573 shares during the period. Hedge funds and other institutional investors own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).